AQB is a micro-cap land-based aquaculture company best known for developing AquAdvantage, a genetically engineered Atlantic salmon. After years of losses and cost overruns, it shut down its Indiana farm, paused the unfinished Ohio Farm Project, and shifted to selling assets and pursuing strategic alternatives. That restructuring has left the stock essentially without analyst coverage: TipRanks lists zero analysts with a 12-month price target, and the last substantive ratings — including a "Neutral" from H.C. Wainwright and "Market Perform" from Oppenheimer in 2024 — predate the wind-down. A single stale $1.00 target dated November 2024 remains in some databases, but it is not a usable, current consensus.
Because no credible aggregate analyst price target exists, the $1.50 figure used here is a fallback objective grounded in public technical discussion rather than a published consensus. It sits meaningfully above the $1.00 Nasdaq minimum-bid threshold the company was required to clear, and it lies within the stock's 52-week trading range, which has reached roughly $2.95. It should be read as a speculative, recovery-scenario milestone — not a forecast any analyst has formally published.
Shares have traded near $0.95, leaving the company with a market value of only a few million dollars. Reaching $1.50 would require approximately 58% appreciation, which is best described as a very large move for any security, even this highly volatile one. The path would depend less on fundamentals than on two catalysts: securing financing and completing a value-creating transaction for the Ohio property. In 2026 management expanded its strategic review to include power generation, digital infrastructure, and energy development uses for the Pioneer, Ohio site — a significant departure from aquaculture. Any credible monetization of that real estate, or a new capital injection, could support a sharp repricing, while continued inaction would likely pressure the shares.
The $1.00 level functions as both a psychological mark and a regulatory compliance threshold, making it a key area to watch; sustained trading below it would refocus attention on listing risk. Above that, $1.50 represents the next round-number resistance zone used here as the target. The 52-week high near $2.95 marks the upper bound of recent trading, while support has formed near the $0.70–$0.77 lows. With very thin average volume and a micro-cap float, technical levels are especially fragile and prone to gap moves.
Because no formal analyst target exists, there is no standard 12-month research horizon to reference; the $1.50 level is a milestone rather than a dated forecast. Investors should monitor the company's quarterly filings and cash balance, any update on the Ohio strategic review and potential energy or infrastructure transaction, further preferred or equity financing and its dilution, and Nasdaq listing-status developments, including the proposed market-value rule. Earnings releases and 8-K filings remain the primary sources of material news for a company with minimal sell-side coverage.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, low-liquidity name such as AQB, automated monitoring can help traders spot changing trends, manage open positions, and surface opportunities more efficiently than manual review. Traders can use the tool to complement their own research and stay alert to momentum shifts across the broader market.
Can AQB reach $1.50? The target is not an analyst-derived consensus but a speculative technical milestone roughly 58% above the recent price. A move of that size is conceivable given the stock's extreme volatility, but it would almost certainly require a transformative event — a monetization of the Ohio property or a substantial capital injection — rather than an improvement in operating fundamentals, because the company's legacy salmon business has been largely wound down. Against that, investors must weigh the going-concern warning, a thin cash position, dilutive financing, and genuine delisting risk. The balance of evidence is cautious, and the outcome will depend on corporate actions and financing rather than earnings. No price target or forecast should be treated as a guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that AQB and EDBL have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AQB and EDBL's prices will move in lockstep.
| Ticker / NAME | Correlation To AQB | 1D Price Change % | ||
|---|---|---|---|---|
| AQB | 100% | -1.03% | ||
| EDBL - AQB | 21% Poorly correlated | +12.68% | ||
| ALCO - AQB | 20% Poorly correlated | +0.03% | ||
| LMNR - AQB | 20% Poorly correlated | +0.19% | ||
| VFF - AQB | 11% Poorly correlated | +0.75% | ||
| CHSCP - AQB | 9% Poorly correlated | +0.04% | ||
More | ||||